About V-type proton ATPase subunit C 1
V-type proton ATPase subunit C 1 (ATP6V1C1) is a protein
from Homo sapiens identified by UniProt accession
P21283, 382 residues long.
MolForge cross-references it against 0 known binders and
76 disease associations.
Target properties
| Protein name | V-type proton ATPase subunit C 1 |
|---|
| UniProt accession | P21283 |
|---|
| Gene | ATP6V1C1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 382 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (76)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.56
- Alzheimer disease · score 0.50
- Parkinson disease · score 0.50
- multiple sclerosis · score 0.50
- lysosomal storage disease · score 0.50
- neuroinflammatory disorder · score 0.27
- PHF-tau measurement · score 0.22
- breast adenocarcinoma · score 0.21
- thyroid gland adenocarcinoma · score 0.18
- glioblastoma multiforme · score 0.14
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P21283-F1 | alphafold | PREDICTED | 91.59 | — |
Amino-acid sequence (382 residues)
MTEFWLISAP GEKTCQQTWE KLHAATSKNN NLAVTSKFNI PDLKVGTLDV LVGLSDELAK LDAFVEGVVK KVAQYMADVL EDSKDKVQEN LLANGVDLVT YITRFQWDMA KYPIKQSLKN ISEIIAKGVT QIDNDLKSRA SAYNNLKGNL QNLERKNAGS LLTRSLAEIV KKDDFVLDSE YLVTLLVVVP KLNHNDWIKQ YETLAEMVVP RSSNVLSEDQ DSYLCNVTLF RKAVDDFRHK ARENKFIVRD FQYNEEEMKA DKEEMNRLST DKKKQFGPLV RWLKVNFSEA FIAWIHVKAL RVFVESVLRY GLPVNFQAML LQPNKKTLKK LREVLHELYK HLDSSAAAII DAPMDIPGLN LSQQEYYPYV YYKIDCNLLE FK
Explore V-type proton ATPase subunit C 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets